Congress Weighs Value Of Pediatric Exclusivity

Law360, New York (June 7, 2007, 12:00 AM EDT) -- Legislation in Congress would lower the amount of market exclusivity that drug makers are awarded for pediatric testing of their drugs, a development the U.S. Food and Drug Administration opposes.

A provision of the U.S. Senate drug user fee bill, S.1082, would lower pediatric exclusivity from six months to three months if the drug is considered a blockbuster, or one that made over $1 billion in annual sales.

The bill has already passed in the Senate. The U.S. House of Representatives is considering how to approach...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.